Alzheimer's disease (AD) is a devastating neurodegenerative disorder that is growing in prevalence globally. It is the only major cause of death without any effective pharmacological means to treat or slow progression. Inheritance of the ε4 allele of the Apolipoprotein (APO) E gene is the strongest genetic risk factor for late-onset AD. The interaction between APOE and amyloid β (Aβ) plays a key role in AD pathogenesis. The APOE-Aβ interaction regulates Aβ aggregation and clearance and therefore directly influences the development of amyloid plaques, congophilic amyloid angiopathy and subsequent tau related pathology. Relatively few AD therapeutic approaches have directly targeted the APOE-Aβ interaction thus far. Here we review the critical role of APOE in the pathogenesis of AD and some of the most promising therapeutic approaches that focus on the APOE-Aβ interaction.

中文翻译：

---

APOE-淀粉样蛋白相互作用：治疗靶点。

阿尔茨海默病 (AD) 是一种毁灭性的神经退行性疾病，在全球范围内日益流行。它是唯一的主要死亡原因，没有任何有效的药理学手段来治疗或减缓进展。载脂蛋白 (APO) E 基因的 ε4 等位基因的遗传是晚发性 AD 的最强遗传风险因素。APOE 和淀粉样蛋白 β (Aβ) 之间的相互作用在 AD 发病机制中起关键作用。APOE-Aβ 相互作用调节 Aβ 的聚集和清除，因此直接影响淀粉样斑块的发展、嗜刚果性淀粉样血管病和随后的 tau 相关病理。迄今为止，相对较少的 AD 治疗方法直接针对 APOE-Aβ 相互作用。